Prognosis Associated with Complete Pathological Response Following Neoadjuvant Treatment for PancreaTic AdenOcarciNOma in the FOFLIRINOX Era: the Multicenter TONO Study.

Date publication

janvier 2025

Journal

Annals of surgical oncology

Auteurs

Membres identifiés du Cancéropôle Est :
Pr BACHELLIER Philippe , Dr FACY Olivier , Pr HEYD Bruno

Tous les auteurs :
Addeo P, Muzzolini M, Laurent C, Heyd B, Sauvanet A, Garnier J, Alfano MS, Gaujoux S, De Ponthaud C, Marchese U, Da Silva D, Buc E, Souche R, Fabre JM, Colombo PE, Ferre L, Foguenne M, Hubert C, El Amrani M, Truant S, Schwartz L, Regenet N, Dupre A, Brustia R, Cherif R, Navez J, Darnis B, Facy O, Grellet R, Piessen G, Veziant J, Rhaiem R, Kianmanesh R, Fernandez-De-Sevilla E, Gelli M, Taibi A, Georges P, Mabrut JY, Lesurtel M, Doussot A, Bachellier P

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/39777595

Résumé

The use of multiagent FOLFIRINOX chemotherapy for pancreatic adenocarcinoma in a neoadjuvant setting has been associated with an increased rate of complete pathological response (CPR) after surgery. This study investigated the long-term outcomes of patients with CPR in a multicenter setting to identify prognostic factors for overall survival (OS) and recurrence-free survival (RFS).

Mots clés

Complete pathologic response, FOLFIRINOX, Neoadjuvant chemotherapy, Pancreatic adenocarcinoma, Radiotherapy

Référence

Ann Surg Oncol. 2025 01 8;: